Trials / Completed
CompletedNCT05527457
BAY2586116 Nasal Spray and OSA Severity
Effects of BAY2586116 on Obstructive Sleep Apnoea (OSA) Severity Informed by Upper Airway Physiology and the Role of Route of Breathing
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Flinders University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This investigator-initiated study aims to determine the effects of BAY2586116 (a novel TASK channel blocker nasal spray) on sleep apnoea severity and the potential influence of route of breathing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY2586116 | 160 μg BAY2586116 nasal spray application |
| DRUG | Placebo | Placebo (saline) nasal spray application |
Timeline
- Start date
- 2022-08-31
- Primary completion
- 2022-12-20
- Completion
- 2022-12-20
- First posted
- 2022-09-02
- Last updated
- 2023-02-15
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT05527457. Inclusion in this directory is not an endorsement.